1. A method of treating an angiogenesis-dependent condition in a mammal in need of such treatment, said method comprising administering to said mammal:
a therapeutically-effective amount of a first antagonist that specifically binds to an extracellular matrix (ECM) component;
a therapeutically-effective amount of a second antagonist that specifically binds to an integrin;
in a combination treatment regimen.
2. The method of claim 1, wherein said angiogenesis-dependent condition is selected from among an angiogenic disease, a cancer-associated disorder and a solid tumor.
3. The method of claim 1, wherein said ECM component specifically bound by said first antagonist is selected from among cryptic collagen epitopes, cryptic laminin epitopes, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
4. The method of claim 1, wherein said integrin is selected from among the integrins listed in Table II.
5. The method of claim 3, wherein said integrin is selected from among the integrins listed in Table II.
6. The method of claim 1, wherein said ECM component bound by said first and second antagonists is denatured laminin.
7. The method of claim 6, wherein said first and said second antagonists bind different or multiple sites on said denatured laminin.
8. The method of claim 1, wherein said first and said second antagonists bind the same ECM component.
9. The method of claim 1, wherein said first and said second antagonists bind different ECM components or multiple sites on the same ECM component.
10. The method of claim 1, wherein said antagonists are selected from among antibodies, antibody fragments, peptides, combinations of antibodies and peptides, and combinations of antibody fragments and peptides.
11. The method of claim 10, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
12. The method of claim 1, further comprising administering one or more chemotherapeutic agents.
13. The method of claim 1, wherein said first antagonist and said second antagonist are administered in combination sequentially or concurrently.
14. The method of claim 2, wherein said cancer is selected from among a cancer of the head neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovary, testes, thyroid, blood, kidney, liver, pancreas, brain, and central nervous system.
15. The method of claim 1, wherein the mammal is a human.
16. A method of treating an angiogenesis-dependent condition in a mammal in need of such treatment, said method comprising administering to said mammal:
a therapeutically-effective amount of a first antagonist that specifically binds to a first extracellular matrix (ECM) component;
a therapeutically-effective amount of a second antagonist that specifically binds to a second ECM component;
in a combination treatment regimen.
17. The method of claim 16, wherein said angiogenesis-dependent condition is selected from among an angiogenic disease, a cancer-associated disorder and a solid tumor.
18. The method of claim 16, wherein said ECM component specifically bound by said first or second antagonist is selected from among cryptic collagen epitopes, cryptic laminin epitopes, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
19. The method of claim 18, wherein said integrin is selected from among the integrins listed in Table II.
20. The method of claim 18, wherein said ECM component is denatured collagen.
21. The method of claim 16, wherein said antagonists are selected from among antibodies, antibody fragments, peptides, combinations of antibodies and peptides, and combinations of antibody fragments and peptides.
22. The method of claim 21, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
23. The method of claim 16, further comprising administering one or more chemotherapeutic agents.
24. The method of claim 16, wherein said first antagonist and said second antagonist are administered in combination sequentially or concurrently.
25. The method of claim 17, wherein said cancer is selected from among a cancer of the head neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovary, testes, thyroid, blood, kidney, liver, pancreas, brain, and central nervous system.
26. The method of claim 16, wherein the mammal is a human.
27. A method of treating an angiogenesis-dependent condition in a mammal in need of such treatment, said method comprising administering to said mammal:
a therapeutically-effective amount of a first antagonist that specifically binds to a first extracellular matrix (ECM) component;
a therapeutically-effective amount of a second antagonist that specifically binds to the same ECM component as said first antagonist;
in a combination treatment regimen
28. The method of claim 27, wherein said angiogenesis-dependent condition is selected from among an angiogenic disease, a cancer-associated disorder and a solid tumor.
29. The method of claim 27, wherein said ECM component specifically bound by said first or second antagonist is selected from among cryptic collagen epitopes, cryptic laminin epitopes, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
30. The method of claim 29, wherein said EMC component is an integrin selected from among the integrins listed in Table II.
31. The method of claim 27, wherein said ECM component is denatured collagen or laminin.
32. The method of claim 27, wherein said first and said second antagonists bind the same site on said ECM component or bind different sites on said same ECM component.
33. The method of claim 27, wherein said antagonists are selected from among antibodies, antibody fragments, peptides, combinations of antibodies and peptides, and combinations of antibody fragments and peptides.
34. The method of claim 33, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
35. The method of claim 27, further comprising administering one or more chemotherapeutic agents.
36. The method of claim 27, wherein said first antagonist and said second antagonist are administered in combination sequentially or concurrently.
37. The method of claim 28, wherein said cancer is selected from among a cancer of the head neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovary, testes, thyroid, blood, kidney, liver, pancreas, brain, and central nervous system.
38. The method of claim 27, wherein the mammal is a human.
39. A method of preventing, treating or managing cancer in a patient in need thereof, said method comprising, administering to said patient:
a dose of an effective amount of an ECM-component antagonist or
an antagonist that competes with the binding of said ECM-component antagonist for binding to the ECM-component; and
a dose of an effective amount of one or more other cancer therapies.
40. The method of claim 39, wherein said ECM-component antagonist is selected from among an ECM-component-binding antibody or an antigen-binding fragment thereof, or an antibody or fragment thereof that competes with said ECM-component-binding antibody for binding to the ECM-component.
41. The method of claim 39, wherein the ECM component is selected from among cryptic collagen epitopes, cryptic laminin epitopes, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
42. The method of claim 39, wherein said antagonist is selected from among a peptide, an antibody or an antigen-binding fragment thereof, a combination of an antibody and peptide, and a combination of an antibody fragment and peptide.
43. The method of claim 42, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
44. The method of claim 39, wherein said ECM-component antagonist or an antagonist that competes with said ECM-component-binding antagonist for binding to the ECM-component, is administered to said patient concurrently or sequentially with the administration of one or more other cancer therapies.
45. The method of claim 39, wherein said one or more other cancer therapies are selected from among administration of an antagonist that bind to a second ECM component, an antagonist that binds to an integrin, one or more chemotherapeutic treatment, one or more biological therapy, one or more immunotherapy, one or more radiation therapy, one or more hormonal therapy, surgery, and a combination thereof.
46. The method of claim 39, wherein said ECM component binding antagonist is an integrin.
47. The method of claim 39, wherein said cancer is selected from among a cancer of the head neck, eye, mouth, throat, esophagus, chest, bone, lung, colon, rectum, stomach, prostate, breast, ovary, testes, thyroid, blood, kidney, liver, pancreas, brain, and central nervous system.
48. The method of claim 39, wherein the patient is a human.
49. A composition, comprising:
a therapeutically effective amount of a first antagonist that specifically binds to a first ECM component and
a therapeutically effective amount of a second antagonist that specifically binds to one of the following selected from among: a second ECM component, a different site on the first ECM component, and an integrin.
50. The composition of claim 49, wherein said ECM-component antagonist is selected from among an ECM-component-binding antibody or an antigen-binding fragment thereof, and an antibody or fragment thereof that competes with said ECM-component-binding antibody for binding to the ECM-component.
51. The composition of claim 49, wherein the ECM component is selected from among a cryptic collagen epitope, cryptic laminin epitope, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
52. The composition of claim 49, wherein said antagonist is selected from among a peptide, an antibody or an antigen-binding fragment thereof, a combination of an antibody and peptide, and a combination of an antibody fragment and peptide.
53. The composition of claim 52, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
54. A composition, comprising:
a therapeutically effective amount of a first antagonist that specifically binds to a first integrin and
a therapeutically effective amount of a second antagonist
wherein the second antagonist specifically binds to one of the following selected from among: a second integrin, a different site on the first integrin, a different component of the first integrin, or a different site on the same component of the first integrin.
55. The composition of claim 54, wherein said ECM-component antagonist is selected from among an ECM-component-binding antibody or an antigen-binding fragment thereof, and an antibody or fragment thereof that competes with said ECM-component-binding antibody for binding to the ECM-component.
56. The composition of claim 54, wherein the ECM component is selected from among a cryptic collagen epitope, cryptic laminin epitope, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
57. The composition of claim 54, wherein said antagonist is selected from among a peptide, an antibody or an antigen-binding fragment thereof, a combination of an antibody and peptide, and a combination of an antibody fragment and peptide.
58. The composition of claim 57, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
59. A composition, comprising:
a therapeutically effective amount of one or more ECM-component antagonist or an antagonist that competes with the binding of an ECM component antagonist to an ECM component and
a therapeutically effective amount of one or more cancer therapies.
60. The composition of claim 59, wherein said one or more cancer therapies are an ECM-component antagonist or an antagonist that competes with the binding of an ECM component antagonist to an ECM component.
61. The composition of claim 60, wherein said ECM-component antagonists are antagonists of the same ECM component or antagonists of different ECM components.
62. The composition of claim 59, wherein said ECM-component antagonist is selected from among an ECM-component-binding antibody or an antigen-binding fragment thereof, and an antibody or fragment thereof that competes with said ECM-component-binding antibody for binding to the ECM-component.
63. The composition of claim 59, wherein the ECM component is selected from among a cryptic collagen epitope, cryptic laminin epitope, fibronectin, vitronectin, fibrinogen, thrombospondin, osteopontin, tenascin and vWF.
64. The composition of claim 59, wherein said antagonist is selected from among a peptide, an antibody or an antigen-binding fragment thereof, a combination of an antibody and peptide, and a combination of an antibody fragment and peptide.
65. The composition of claim 64, wherein the antibody fragment is a fragment selected from among a Fab, a F(ab\u2032)2, a Fv, a scFv, a Fd and a single chain binding polypeptide.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for increasing system capacity for a wireless communication environment, comprising:
evaluating whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips;
defining a plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded;
assigning a unique scrambling code to one of the plurality of Walsh code clusters having a set of orthogonal Walsh code sequences which are reused, based upon spatial information; and
assigning a Walsh code sequence to a user device.
2. The method of claim 1, further comprising determining whether a spatial signature for a first user device is within a predetermined threshold range of a spatial signature for a second user device.
3. The method of claim 2, wherein the predetermined threshold range is based at least in part on a distance within which the first and second user devices will interfere with each other when assigned identical Walsh codes.
4. The method of claim 1, further comprising assigning a first and second user devices to different Walsh code clusters upon a determination that spatial signatures for the first and second user devices are outside a predetermined threshold range.
5. The method of claim 1, further comprising assigning a first and second user devices to a same Walsh code cluster upon a determination that spatial signatures for the first and second user devices are within a predetermined threshold range.
6. The method of claim 5, user devices within the same Walsh code cluster are assigned orthogonal Walsh code sequences.
7. The method of claim 1, wherein multiple Walsh code clusters are defined as having duplicate sets of orthogonal Walsh codes.
8. The method of claim 1, the wireless communication environment employs a wideband code-division multiple access protocol.
9. A wireless communication apparatus, comprising:
a memory that stores information related to a plurality of Walsh code clusters with at least one Walsh code cluster that comprises a set of orthogonal Walsh code sequences; and
a processor, coupled to the memory, wherein the processor:
a) evaluates whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips;
b) defines the plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded; and
c) assigns a unique scrambling code to the at least one Walsh code cluster, and assigns a Walsh code sequence which is reused to a user device.
10. The apparatus of claim 9, wherein the memory stores a lookup table comprising information related to Walsh code clusters, Walsh code sequences in each cluster, user device assignments of Walsh code sequences, and scrambling codes assigned to each cluster.
11. The apparatus of claim 10, wherein the processor evaluates spatial signatures associated with user devices in the sector and groups the user devices into subsets based at least in part on the spatial signatures of the user devices.
12. The apparatus of claim 11, wherein the processor assigns subsets of user devices in the sector to a code cluster.
13. The apparatus of claim 12, wherein the processor further assigns each of the user devices in a subset to a different orthogonal Walsh code sequence in the cluster to mitigate interference between user devices in the same cluster.
14. The apparatus of claim 10, wherein the processor assigns a unique scrambling code to each cluster to differentiate between clusters.
15. The apparatus of claim 14, wherein the scrambling code is a pseudo-noise code.
16. The apparatus of claim 9, wherein the wireless communication apparatus communicates according to a wideband code-division multiple access protocol.
17. The apparatus of claim 9, wherein the wireless communication apparatus communicates according to at least one of time-division duplexed and frequency-division duplexed communication.
18. An apparatus for increasing system capacity in a sector of a wireless communication environment, comprising:
means for evaluating whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips;
means for defining a plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded;
means for generating the plurality of Walsh code clusters that have a complete set of orthogonal Walsh sequences;
means for assigning a unique scrambling code to each of the plurality of Walsh code clusters; and
means for assigning user device subsets to the plurality of Walsh code clusters, wherein each user device is assigned at least one orthogonal Walsh sequence which is reused in one of the plurality of Walsh code clusters.
19. The apparatus of claim 18 further comprising means for evaluating spatial signatures for a set of user devices in the sector and grouping the user devices into subsets based at least in part on respective spatial signatures.
20. The apparatus of claim 19, further comprising means for scaling the number of Walsh code clusters according to system demand in the sector, such that all user devices are assigned at least one orthogonal Walsh sequence.
21. The apparatus of claim 19, the wireless communication environment employs a wideband code-division multiple access protocol.
22. The apparatus of claim 21, the wireless communication environment is at least one of time-division duplexed and frequency-division duplexed.
23. A non-transitory computer-readable medium having stored thereon computer-executable instructions for:
evaluating whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips;
defining a plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded;
generating the plurality of Walsh code clusters that each have a complete set of orthogonal Walsh sequences;
assigning a unique scrambling code to each of the plurality of Walsh code clusters to uniquely identify each of the plurality of Walsh code clusters; and
assigning user device subsets to the plurality of Walsh code clusters wherein each user device is assigned at least one orthogonal Walsh sequence which is reused in one of the plurality of Walsh code clusters.
24. The non-transitory computer-readable medium of claim 23 further comprising instructions for grouping user devices in the sector into subsets based at least in part on a spatial signature associated with each user device.
25. The non-transitory computer-readable medium of claim 24, further comprising means for scaling the number of Walsh code clusters according to system demand in the sector, such that all user devices are assigned at least one orthogonal Walsh sequence.
26. A processor that executes instructions for increasing system capacity in a wideband code-division multiple access wireless communication environment, the instructions comprising:
evaluating whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips;
defining a plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded;
generating the plurality of Walsh code clusters that each have a complete set of orthogonal Walsh sequences;
assigning user device subsets to the plurality of Walsh code clusters wherein each user device is assigned at least one orthogonal Walsh sequence which is reused in one of the plurality of Walsh code clusters and wherein subsets are generated based at least in part on spatial signatures of the user devices; and
assigning a unique scrambling code to each of the plurality of Walsh code clusters to distinguish between each of the plurality of Walsh code clusters.
27. A mobile device that facilitates communicating over a wireless network, comprising:
a component that evaluates whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips;
a component that defines a plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded;
a component that receives an assignment of a Walsh code sequence which is reused in one of the plurality of Walsh code clusters;
a component that recognizes whether the Walsh code sequence in an incoming signal is assigned to the mobile device; and
a component that recognizes whether an expected scrambling code associated with one of the plurality of the Walsh code clusters is present in the incoming signal;
wherein the mobile device disregards as pseudo-noise an incoming signal that does not exhibit both the assigned Walsh code sequence and the expected scrambling code.
28. The mobile device of claim 27, wherein the device is at least one of a cellular phone, a smartphone, a handheld communication device, a handheld computing device, a satellite radio, a global positioning system, a laptop, and a PDA.
29. A method of increasing system capacity in a wireless communication environment, comprising:
evaluating whether system capacity has been exceeded, wherein the system capacity is the maximum number N of users with unique Walsh codes of length N chips which are reused;
defining a plurality of Walsh code clusters sufficient to meet system requirements when system capacity has been exceeded;
assigning user devices with similar spatial signatures to a same Walsh code cluster in the plurality of Walsh code clusters; and
assigning user devices with sufficiently different spatial signatures to different Walsh code clusters.
30. The method of claim 29, further comprising assigning a unique scrambling code to each of the plurality of Walsh code clusters to distinguish between each of the plurality of Walsh code clusters.
31. The method of claim 29, further comprising defining a predetermined spatial threshold range that delineates spatial boundaries between user devices.
32. The method of claim 31, further comprising assigning user devices to the same code cluster when their spatial signatures are within the predetermined spatial threshold range of each other.
33. The method of claim 31, further comprising assigning user devices to different code clusters when their spatial signatures are not within the predetermined spatial threshold range of each other.
34. The method of claim 33, further comprising permitting assignment of identical Walsh code sequences in different code clusters to user devices assigned to different code clusters.